1(R)-(N-benzyloxycarbonylamino)ethylphosphinic acid | 115115-40-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1(R)-(N-benzyloxycarbonylamino)ethylphosphinic acid
• 英文别名: (R)-1-(N-benzyloxycarbonylamino)ethylphosphinic acid；(R)-[1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinic acid；(R)-(1-benzyloxycarbonylamino-ethyl)phosphinic acid；[(1R)-1-(phenylmethoxycarbonylamino)ethyl]phosphinic acid
• CAS: 115115-40-7
• 化学式: C₁₀H₁₄NO₄P
• 分子量: 243.199
• InChiKey: KHVQOUDIMLMPNA-MRVPVSSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1(R)-(N-benzyloxycarbonylamino)ethylphosphinic acid 在 sodium hydroxide 、 N,O-双三甲硅基乙酰胺 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 生成 (S)-2-{2-Benzyl-3-[((R)-1-benzyloxycarbonylamino-ethyl)-hydroxy-phosphinoyl]-propionylamino}-3-phenyl-propionic acid methyl ester
  参考文献：
  名称：

  Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor

  摘要：

  A series of phosphinic compounds mimicking the transition state of substrates hydrolysed by aminopeptidase N (EC 3.4.11.2) were synthesized. These new compounds have potent inhibitory activities with Ki values in the nanomolar range. These derivatives behave as the most potent APN inhibitors designed to date.

  DOI：

  10.1016/s0960-894x(99)00219-x
• 作为产物：
  描述：

  benzyloxycarbonyl-1-aminoethyl-1-phosphinate 在 R(+)-alpha-甲基苄胺 作用下， 以 乙酸乙酯 、 异丙醇 为溶剂， 以86%的产率得到1(R)-(N-benzyloxycarbonylamino)ethylphosphinic acid
  参考文献：
  名称：

  AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN

  摘要：

  本发明涉及以下通式（I）的化合物：R1—NH—CH（R2）—P（═O）（OR3）—CH2—C（R4）（R5）—CONH—CH（R6）—COOR7或其药学上可接受的盐、异构体或任意比例的异构体混合物，特别是对映体混合物，尤其是外消旋混合物，其中R1代表—C（═O）—O—C（R8）（R9）—OC（═O）—R10基团；R2代表可选取代的碳氢链、芳基或杂环芳基基团或被杂环取代的亚甲基基团；R3代表氢原子或—C（R12）（R13）—OC（═O）—R14基团；R4和R5与承载它们的碳原子一起形成饱和碳氢基环或可选取代的哌啶环或R4代表氢原子，R5代表可选取代的苯基或苄基、杂环芳基环或被杂环取代的亚甲基基团；R6代表可选取代的碳氢链或可选取代的苯基或苄基；R7代表氢原子或苄基、烷基、杂环芳基、烷基杂环芳基、—CHMe—COOR18、—CHR19—OC（═O）OR20和—CHR19—OC（═O）OR20基团。本发明还涉及这些化合物作为药物的用途，特别是用于疼痛治疗，更有利的是神经病理性和神经炎性疼痛的治疗，以及它们的合成方法和含有它们的组合物。

  公开号：

  US20110124601A1

文献信息

• AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN
  申请人：Roques Bernard

  公开号：US20110124601A1

  公开（公告）日：2011-05-26

  The present invention relates to a compound of the following general formula (I): R 1 —NH—CH(R 2 )—P(═O)(OR 3 )—CH 2 —C(R 4 )(R 5 )—CONH—CH(R 6 )—COOR 7 (I) or a pharmaceutically acceptable salt of the latter, an isomer or a mixture of isomers in any proportions, especially a mixture of enantiomers, and in particular a racemic mixture, for which R 1 represents a —C(═O)—O—C(R 8 )(R 9 )—OC(═O)—R 10 group; R 2 represents an optionally substituted hydrocarbon-based chain, an aryl or heteroaryl group or a methylene group substituted by a heterocycle; R 3 represents a hydrogen atom or a —C(R 12 )(R 13 )—OC(═O)—R 14 group; R 4 and R 5 form, together with the carbon that bears them, a saturated hydrocarbon-based ring or an optionally substituted piperidine ring or R 4 represents a hydrogen atom and R 5 represents a phenyl or a benzyl that is optionally substituted, a heteroaromatic ring or a methylene group substituted by a heterocycle; R 6 represents an optionally substituted hydrocarbon-based chain or a phenyl or a benzyl that is optionally substituted; and R 7 represents a hydrogen atom or a benzyl, alkyl, heteroaryl, alkylheteroaryl, —CHMe—COOR 18 , —CHR 19 —OC(═O)OR 20 and —CHR 19 —OC(═O)OR 20 group. The present invention also relates to the use of these compounds as a medicinal product, and in particular for the treatment of pain, more advantageously neuropathic and neuroinflammatory pain, to their method of synthesis and also to the compositions containing them.

  本发明涉及以下通式（I）的化合物：R1—NH—CH（R2）—P（═O）（OR3）—CH2—C（R4）（R5）—CONH—CH（R6）—COOR7或其药学上可接受的盐、异构体或任意比例的异构体混合物，特别是对映体混合物，尤其是外消旋混合物，其中R1代表—C（═O）—O—C（R8）（R9）—OC（═O）—R10基团；R2代表可选取代的碳氢链、芳基或杂环芳基基团或被杂环取代的亚甲基基团；R3代表氢原子或—C（R12）（R13）—OC（═O）—R14基团；R4和R5与承载它们的碳原子一起形成饱和碳氢基环或可选取代的哌啶环或R4代表氢原子，R5代表可选取代的苯基或苄基、杂环芳基环或被杂环取代的亚甲基基团；R6代表可选取代的碳氢链或可选取代的苯基或苄基；R7代表氢原子或苄基、烷基、杂环芳基、烷基杂环芳基、—CHMe—COOR18、—CHR19—OC（═O）OR20和—CHR19—OC（═O）OR20基团。本发明还涉及这些化合物作为药物的用途，特别是用于疼痛治疗，更有利的是神经病理性和神经炎性疼痛的治疗，以及它们的合成方法和含有它们的组合物。
• (&agr;-aminophosphino) peptides derivative and compositions containing same
  申请人：Institut National de la Sante et de la Recherche Medicale (Inserm)

  公开号：US06391866B1

  公开（公告）日：2002-05-21

  The invention concerns (&agr;-aminophosphino) peptide derivative compounds of general formula (I) wherein: R1 and R2 represent each a hydrogen atom or together form an imine with the adjacent nitrogen atom; R3 represents an alkyl group, an alkenyl group, a phenyl group, a benzyl group, all said groups capable of being substituted or not, a hydrogen atom, a cycloalkyl group, a cycloalkylmethyl group or finally a methyl group substituted by an aromatic or saturated heterocyclic group; R4 represents a CH(X)—(O)—C(O)—Y group or a CH2CH2—S—C(O)—W group; R5 represents an alkyl group, an alkenyl group, a phenyl group, a benzyl group, all said groups capable of being substituted or not, a hydrogen atom, a cycloalkyl group, a cycloalkylmethyl group or finally a methyl group substituted by an aromatic or unsaturated heterocyclic group; R6 and R7 can in particular represent a hydrogen atom, an alkyl group, a phenyl group substituted or not; R8 represents an alkyl, alkenyl, phenyl or benzyl group; n=0 or 1, in the form of enantiomers, diastereoisomers or racemic mixtures, their salts, the method for preparing them and their therapeutic applications.

  该发明涉及一般式（I）的（α-氨基膦）肽衍生物化合物，其中：R1和R2分别表示氢原子或与相邻氮原子形成亚胺；R3表示烷基、烯基、苯基、苄基，所有这些基团都可以被取代或不取代，氢原子、环烷基、环烷基甲基基团或最终被芳香族或饱和杂环基团取代的甲基基团；R4表示CH(X)—(O)—C(O)—Y基团或CH2CH2—S—C(O)—W基团；R5表示烷基、烯基、苯基、苄基，所有这些基团都可以被取代或不取代，氢原子、环烷基、环烷基甲基基团或最终被芳香族或不饱和杂环基团取代的甲基基团；R6和R7特别表示氢原子、烷基、苯基，可取代或不取代；R8表示烷基、烯基、苯基或苄基；n=0或1，以对映体、非对映异构体或混合物形式存在，它们的盐、制备方法及其治疗应用。
• Practical Synthesis of Phosphinic Dipeptides by Tandem Esterification of Aminophosphinic and Acrylic Acids under Silylating Conditions
  作者：Paraskevi Kokkala、Kostas Voreakos、Angelos Lelis、Konstantinos Patiniotis、Nikolaos Skoulikas、Laurent Devel、Angeliki Ziotopoulou、Eleni Kaloumenou、Dimitris Georgiadis

  DOI：10.3390/molecules27041242

  日期：——

  acrylic acids and (R)-α-aminophosphinic acids, and high yields were achieved in all cases. In most examples reported herein, the isolation of biologically relevant (R,S)-diastereoisomers became possible by simple crystallization from the crude products, thus enhancing the operational simplicity of the proposed method. Finally, functional groups corresponding to acidic or basic natural amino acids are also

  在本报告中，提出了一种制备 5 型次膦酸二肽的合成方案。这些化合物可作为开发药用相关锌金属蛋白酶和天冬氨酰蛋白酶的高效膦肽抑制剂的重要组成部分。所提出的方法基于 α-氨基次膦酸和丙烯酸在甲硅烷基化条件下的串联酯化，以便随后参与 P-Michael 反应。通过使用多种容易获得的丙烯酸和 (R)-α-氨基次膦酸来研究转化的范围，并且在所有情况下都实现了高产率。在本文报道的大多数例子中，生物学相关的 (R,S)-非对映异构体的分离成为可能通过从粗产物中简单结晶，从而提高了所提出方法的操作简单性。最后，对应于酸性或碱性天然氨基酸的官能团也与反应条件相容。基于以上所述，我们预计所提出协议的实用性将有助于发现药理上有用的生物活性次膦酸肽。
• Diastereoselective Solution and Multipin-Based Combinatorial Array Synthesis of a Novel Class of Potent Phosphinic Metalloprotease Inhibitors
  作者：Anastasios Makaritis、Dimitris Georgiadis、Vincent Dive、Athanasios Yiotakis

  DOI：10.1002/chem.200204456

  日期：2003.5.9

  preparation of a novel class of isoxazole-containing phosphinic peptides (peptides 5 a-i). Solid-phase version of this strategy was efficiently achieved on multipin solid technology, by developing a new protocol for the coupling of P-unprotected dipeptidic blocks with solid supported amino acids in a quantitative and diastereoselective manner. Optimization of dipolar cycloadditions onto pin-embodied

  以高收率和光学纯度（3 ad单元）实现了含有三键的新膦肽肽结构单元的溶液相合成和拆分。通过NMR研究明确地确定了目标化合物的绝对构型。这些嵌段的组装后多样化策略是通过各种原位制备的腈氧化物的1，3-偶极环加成反应开发的。该策略导致快速有效地非对映选择性地制备了新型的含异恶唑的次膦酸肽（肽5 ai）。通过开发一种新的方案，可以定量和非对映选择性地将P-未保护的二肽嵌段与固体负载的氨基酸偶联，从而在多针固体技术上有效地实现了该策略的固相形式。偶极次膦肽上偶极环加成反应的优化使得可以方便地制备这种新型的伪肽。如通过RP-HPLC测定，以高产率和纯度获得粗品次膦肽（9ak）。这些肽中的某些的抑制分析表明，它们在效力方面表现出非常强的MMP抑制剂的性能，与以前报道的次膦酸酯肽相媲美（K（i）在几nM范围内）。
• Phosphinic Derivatives as New Dual Enkephalin-Degrading Enzyme Inhibitors: Synthesis, Biological Properties, and Antinociceptive Activities
  作者：Huixiong Chen、Florence Noble、Aurélie Mothé、Hervé Meudal、Pascale Coric、Sophie Danascimento、Bernard P. Roques、Pascal George、Marie-Claude Fournié-Zaluski

  DOI：10.1021/jm990483l

  日期：2000.4.6

  The development of dual inhibitors of the two zinc metallopeptidases, neprilysin (neutral endopeptidase) and aminopeptidase N involved in the inactivation of the opioid peptides, enkephalins, represents an attractive physiological approach in the search for new analgesics devoid of the major drawbacks of morphine. Phosphinic compounds, corresponding to the general formula H(3)N(+)-CH(R(1))-P(O)(OH

  涉及阿片类肽脑啡肽失活的两种锌金属肽酶，中性溶酶（中性内肽酶）和氨基肽酶N双重抑制剂的开发代表了一种寻找新的止痛药的有吸引力的生理方法，该止痛药没有吗啡的主要缺点。对应于通式H（3）N（+）-CH（R（1））-P（O）（OH）-CH（2）-CH（R（2））-CONH-CH（ R（3））-COO（-），能够充当过渡态类似物并适合两种酶的S（1），S（1）'和S（2）'亚位点。选择R（1），R（2）和R（3）残基以最佳识别这些酶，导致了首个双重竞争抑制剂，其脑啡肽酶和氨基肽酶N的K（i）值在纳摩尔范围内。